Detection of nucleic acids by type specific hybrid capture method

• US 7,829,691 B2
• Filed: 10/19/2008
• Issued: 11/09/2010
• Est. Priority Date: 06/15/2000
• Status: Expired due to Fees

• Current Assignee: QIAGEN Gaithersburg, Inc. (Qiagen NV)
• Original Assignee: QIAGEN Gaithersburg, Inc. (Qiagen NV)
• Inventors: Lorincz, Attila, Anthony, James, Troy, John, Tan, Yanglin
• Primary Examiner(s): Chunduru; Suryaprabha
• Application Number:
  US12/253,976
• Publication Number:
  US 20090162851A1
• Time in Patent Office: 751 Days
• Field of Search: 536/22.1, 536/24.32, 435/6
• US Class Current: 536/24.32
• CPC Class Codes: C12Q 1/6832 Enhancement of hybridisation reaction
• CPC Class Codes: C12Q 1/6834 Enzymatic or biochemical coupling of nucleic acids to a solid phase
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 1/705 for herpetoviridae, e.g. herpes simplex, varicella zoster
• CPC Class Codes: C12Q 1/708 for papilloma
• CPC Class Codes: C12Q 2525/186 incorporating a non-extendable or blocking moiety
• CPC Class Codes: C12Q 2565/519 characterised by the capture moiety being a single stranded oligonucleotide
• CPC Class Codes: C12Q 2565/543 characterised by the use of two or more capture oligonucleotide primers in concert, e.g. bridge amplification
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

Target-specific hybrid capture (TSHC) provides a nucleic acid detection method that is not only rapid and sensitive, but is also highly specific and capable of discriminating highly homologous nucleic acid target sequences. The method produces DNA-RNA hybrids which can be detected by a variety of methods.

Claims

1. A composition for detecting a viral nucleic acid comprising:

at least two capture sequence probes, wherein each capture sequence probe consists of a nucleic acid sequence selected from the group consisting of SEQ ID NO;

1 through SEQ ID No;

29, SEQ ID NO;

50 through SEQ ID NO;

62, SEQ ID NO;

75 through SEQ ID NO;

109, SEQ ID NO;

152 through SEQ ID NO;

154, and wherein at least one capture sequence probe is hybridized to a first region of the viral nucleic acid, and

at least one blocker sequence probe, wherein the blocker sequence probe consists of a nucleic acid sequence selected from the group consisting of SEQ ID NO;

30 through SEQ ID No;

49, SEQ ID NO;

63 through SEQ ID NO;

74, SEQ ID NO;

110 through SEQ ID NO;

151, SEQ ID NO;

155 through SEQ ID NO;

160, and wherein the blocker sequence probe is hybridized to at least one capture sequence probe that is not hybridized to the first region of viral nucleic acid.

2. The composition of claim 1, further comprising at least one signal sequence probe complementary to a second region of the viral nucleic acid,

wherein the second region of the viral nucleic acid does not overlap with the first region of the viral nucleic acid, and

wherein the signal sequence probe is hybridized to the second region of the viral nucleic acid forming a double-stranded hybrid and wherein the signal sequence probe is not hybridized to the capture sequence probe.

3. The composition of claim 1, wherein the capture sequence probe is captured onto a solid phase.

4. The composition of claim 1, wherein the viral nucleic acid is from HSV-1.

5. The composition of claim 1, wherein the viral nucleic acid is from HSV-2.

6. The composition of claim 1, wherein the viral nucleic acid is from HPV.

7. The composition of claim 1, wherein the viral nucleic acid is from HBV.

8. The composition of claim 1, wherein the capture sequence probe is modified with at least one ligand.

9. The composition of claim 2, wherein the signal sequence probe is unlabelled.

10. The composition of claim 8, wherein the ligand is biotin.

11. The composition of claim 10, wherein the capture sequence probe is linear having a 5′

and 3′

end, wherein both the 5′ and

the 3′

ends are biotinylated.

12. The composition of claim 2, wherein the first region of the viral nucleic acid and the second region of the viral nucleic acid are less than 3 kilobases apart.

13. The composition of claim 2, wherein the first region of the viral nucleic acid and the second region of the viral nucleic acid are less than 500 bases apart.

14. The composition of claim 1, wherein the capture sequence probe is a fusion of two or more sequences complementary to different regions of the same viral nucleic acid or to different viral nucleic acids.

15. The composition of claim 2, wherein the double-stranded hybrid formed is a DNA-RNA hybrid.

16. The composition of claim 1, wherein the blocker probe has a lower melting temperature than that of the capture sequence probe.

17. The composition of claim 3, wherein the solid phase is coated with streptavidin.

18. The composition of claim 3, wherein the solid phase is a microplate.

19. The composition of claim 1, wherein the composition is maintained at room temperature.

20. The composition of claim 2, further comprising an antibody capable of recognizing a hybrid, wherein the antibody is bound to the double-stranded hybrid.

21. The composition of claim 20, wherein the double-stranded hybrid is a DNA-RNA-hybrid and the antibody is capable of recognizing a DNA-RNA-hybrid.

22. The composition of claim 21, wherein the antibody capable of recognizing a DNA-RNA hybrid is labeled with alkaline-phosphatase.

24. The composition of claim 2, wherein the signal sequence probe comprises a DNA-RNA duplex and a single stranded nucleic acid sequence which is capable of hybridizing to the viral nucleic acid.

25. The composition of claim 24, wherein the DNA-RNA duplex is an M13 DNA-M13 RNA duplex.

23. A nucleic acid probe set comprising:

(1) at least one capture sequence probe specific for a virus selected from the group consisting of;

HPV, HBV, HSV-1, and HSV-2, wherein the capture sequence probe consists of a sequence selected from the group consisting of;

SEQ ID NO;

1 through SEQ ID NO;

29, SEQ ID NO;

50 through SEQ ID NO;

62, SEQ ID NO;

75 through SEQ ID NO;

109, and SEQ ID NO;

152 through SEQ ID NO;

154; and

(2) at least one blocker sequence probe specific for the capture sequence probe, wherein the blocker sequence probe consists of a sequence selected from the group consisting of;

SEQ ID NO;

30 ;

through SEQ ID NO;

49, SEQ ID NO;

63 through SEQ ID NO;

74, SEQ ID NO;

110 through SEQ ID NO;

151, and SEQ ID NO;

155 through SEQ ID NO;

160.

26. A kit for detecting a viral nucleic acid comprising:

(1) a capture sequence probe consists of a nucleic acid sequence selected from the group consisting of SEQ ID NO;

1 through SEQ ID NO;

29, SEQ ID NO;

50 through SEQ ID NO;

62, SEQ ID NO;

75 through SEQ ID NO;

109, SEQ ID NO;

152 through SEQ ID NO;

154, wherein the capture sequence probe is complementary to a first region of the viral nucleic acid; and

(2) a blocker sequence probe consists of a nucleic acid sequence selected from the group consisting of SEQ ID NO;

30 through SEQ ID NO;

49, SEQ ID NO;

63 through SEQ ID NO;

74, SEQ ID NO;

110 through SEQ ID NO;

151, SEQ ID NO;

155 through SEQ ID NO;

160.

27. The kit of claim 26, further comprising a signal sequence probe complementary to a second region of the viral nucleic acid, wherein the second region of the viral nucleic acid does not overlap with the first region of the viral nucleic acid, and wherein the signal sequence probe is not capable of hybridizing to the capture sequence probe.

28. The kit of claim 26 wherein the capture sequence probe further comprises at least one modification which allows specific capture of the capture sequence probe onto a solid phase.

29. The kit of claim 26, wherein the viral nucleic acid is from HSV-1.

30. The kit of claim 26, wherein the viral nucleic acid is from HSV-2.

31. The kit of claim 26, wherein the viral nucleic acid is from HPV.

32. The kit of claim 26, wherein the viral nucleic acid is from HBV.